Pfizer

A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.

A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.

Stocks closed a lightly traded session higher Tuesday despite disappointing earnings from Goldman Sachs and Johnson & Johnson.

Last week, Standard & Poor's lent its insight into European companies ripe for being acquired. This week, the firm's analysts are taking a look at who might do the buying.